Form 4: Arvinas Inc. Executive Angela M. Cacace Reports Stock and Option Awards

Angela M. Cacace, Chief Scientific Officer of Arvinas Inc., reports the acquisition of restricted stock units and stock options, signaling potential future ownership in the company.

Summary

• On February 13, 2025, Angela M. Cacace, Chief Scientific Officer of Arvinas Inc., was granted 49,092 restricted stock units (RSUs) and an option to purchase 74,960 shares of common stock.
• The RSUs will vest over four years, with 25% vesting annually on February 13th from 2026 to 2029, contingent upon continued service.
• The stock options, with an exercise price of $17.67, also vest over four years, starting February 13, 2026, with the remainder vesting in equal monthly installments until February 13, 2029, subject to continued service.
• Following these transactions, Cacace directly owns 100,944 shares of Arvinas Inc. common stock and options to purchase 74,960 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects standard executive compensation practices, incentivizing key personnel and aligning their interests with shareholders. There are no immediate negative implications.

Positives

• The grant of RSUs and stock options to a key executive like the Chief Scientific Officer suggests an incentive alignment with the company's long-term performance.
• The vesting schedule encourages continued service and commitment from Angela M. Cacace over the next four years.

Risks

• The value of the RSUs and stock options is contingent on the future performance of Arvinas Inc.'s stock price.
• If Angela M. Cacace leaves the company before the vesting dates, she will forfeit the unvested RSUs and stock options.

Future Outlook

The document does not contain explicit forward-looking statements, but the equity grants suggest an expectation of continued growth and value creation at Arvinas Inc.

Industry Context

Equity compensation is a common practice in the biotechnology industry to attract, retain, and incentivize key personnel. The size and vesting schedule of these grants are typical for a Chief Scientific Officer at a company like Arvinas Inc.

Comparison to Industry Standards

• Comparing Arvinas' equity compensation practices to similar biotech companies like Relay Therapeutics or Monte Rosa Therapeutics, the size of the grants appears to be within the typical range for executive-level compensation.
• The four-year vesting schedule is also a standard practice in the industry, aligning with long-term value creation and retention goals.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align executive compensation with company performance.
• Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

Keywords

Arvinas Inc., Angela M. Cacace, restricted stock units, stock options, beneficial ownership, Form 4, ARVN, Chief Scientific Officer, equity compensation, vesting